Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Home/ Catalogue/ Immune & Antimicrobial/ Thymosin Alpha-1
In stock
Thymosin Alpha-1

Thymosin Alpha-1

Lyophilised · ≥99% (HPLC) ·

Quantity Volume discounts auto-applied
Custom quantity
1

Supplied lyophilised. Reconstitution typically uses bacteriostatic water.

Independently third-party tested · COA on every batch · 48h EU dispatch
[01]

Overview

Thymosin Alpha-1 (Tα1) is a synthetic 28-amino-acid peptide originally isolated from thymosin fraction 5 of bovine thymus, studied extensively in immunomodulation, dendritic cell maturation, and T-cell signalling research. CAS 62304-98-7; sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH; molecular weight 3108.36 g/mol; supplied lyophilised at ≥99% purity by HPLC. For laboratory research use only; not for human or veterinary use.

First isolated from a fraction of calf thymus that restored immune competence, Thymosin Alpha-1 is a synthetic 28-amino-acid acetylated peptide identical to a naturally occurring thymic hormone. As a central immunomodulator, it has become one of the most extensively investigated peptides in the study of host defence, inflammation, and immune homeostasis.

A messenger from the immune system's training ground. The thymus orchestrates the maturation of T cells, and Thymosin Alpha-1 is one of the signalling peptides it produces. Research established that the molecule helps tune the balance of immune responses — promoting T-cell differentiation and modulating innate and adaptive arms alike — which positioned it as a versatile experimental tool for probing immune regulation (King et al., 2016; Garaci et al., 2024).

What the research explores. The peptide spans a remarkably broad investigational landscape:

  • Immune modulation — characterised for its effects on T-cell maturation and immune-response balance (King et al., 2016; Dominari et al., 2020).
  • Inflammation & infection — studied in models of severe inflammation and sepsis (Pei et al., 2018; Tian et al., 2025).
  • Endogenous physiology — serum levels have been profiled across normal and pathological conditions (Pica et al., 2018).
  • Ageing biology — examined in the context of immunosenescence and ageing (Simonova et al., 2025).

All such findings originate from in vitro, animal, and clinical research; no human-use conclusions are supported by this listing. Full citations are listed under the Scientific References tab.

Physicochemical profile. CAS 62304-98-7 · Molecular formula C₁₂₉H₂₁₅N₃₃O₅₅ · Molecular weight 3108.3 · Sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn · Appearance: white lyophilized powder · Solubility: soluble in water.

Specification & quality. Each individually sealed vial contains 10 mg of Thymosin Alpha-1 as a white lyophilized powder of ≥99% purity by HPLC. Every batch is third-party tested, with a Certificate of Analysis (COA) available. Store at −20 °C, protected from light and moisture. Shelf life: 24 months from the manufacture date.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.

Supplied for in-vitro laboratory research use only (RUO). Not a drug, food or supplement; not for human or veterinary use.

[04]

Quality & COA

Certificate of Analysis
Lot-specific COA with every order

Certificate of Analysis — lot-specific COA ships with every order and is available on request.

Each lot is tested by an independent third-party laboratory for identity (mass spectrometry) and purity (HPLC). The Certificate of Analysis for your specific batch ships with the order and is available on request — no house data, no exceptions.

HPLC purity
≥99% (HPLC)
Method
HPLC + MS
Endotoxin
Reported
[02]

Data Sheet

CAS number62304-98-7
Molecular formulaC₁₂₉H₂₁₅N₃₃O₅₅
Molecular weight3108.3
SequenceAc-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn
Purity≥99% (HPLC)
Physical formWhite lyophilized powder
Quantity10mg/vial
SolubilitySoluble in water
StorageStore at -20°C, protect from light
Shelf life24 months from manufacture date
OriginEU · Slovakia
ClassificationResearch use only
[03]

Scientific References

01 Simonova MA, Ivanov I, Shoshina NS, Komyakova AM, Makarov DA, Baranovskii DS, et al. Aging and Thymosin Alpha-1. Int J Mol Sci. 2025;26(23). PMID: 41373628. doi:10.3390/ijms262311470. PubMed 02 Tian Y, Yao J, Ma Y, Zhang P, Zhou X, Xie W, et al. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. Front Immunol. 2025;16:1571456. PMID: 40599771. doi:10.3389/fimmu.2025.1571456. PubMed 03 Cao A, Feng F, Zhou X. Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. J Coll Physicians Surg Pak. 2024;34(12):1497-1507. PMID: 39648386. doi:10.29271/jcpsp.2024.12.1497. PubMed 04 Yu J, Wang Q, Wang L, Zong D, He X. PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review. Medicine (Baltimore). 2024;103(34):e39271. PMID: 39183403. doi:10.1097/MD.0000000000039271. PubMed 05 Garaci E, Paci M, Matteucci C, Costantini C, Puccetti P, Romani L. Phenotypic drug discovery: a case for thymosin alpha-1. Front Med (Lausanne). 2024;11:1388959. PMID: 38903817. doi:10.3389/fmed.2024.1388959. PubMed 06 Dinetz E, Lee E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Altern Ther Health Med. 2024;30(1):6-12. PMID: 38308608. PubMed 07 Soeroto AY, Suryadinata H, Yanto TA, Hariyanto TI. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology. 2023;31(6):3317-3325. PMID: 37845598. doi:10.1007/s10787-023-01354-2. PubMed 08 Dominari A, Hathaway Iii D, Pandav K, Matos W, Biswas S, Reddy G, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. PMID: 33362999. doi:10.5501/wjv.v9.i5.67. PubMed 09 Peng D, Xing HY, Li C, Wang XF, Hou M, Li B, et al. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20(1):348. PMID: 33076834. doi:10.1186/s12876-020-01477-8. PubMed 10 Pei F, Guan X, Wu J. Thymosin alpha 1 treatment for patients with sepsis. Expert Opin Biol Ther. 2018;18(sup1):71-76. PMID: 30063866. doi:10.1080/14712598.2018.1484104. PubMed 11 Pica F, Gaziano R, Casalinuovo IA, Moroni G, Buè C, Limongi D, et al. Serum thymosin alpha 1 levels in normal and pathological conditions. Expert Opin Biol Ther. 2018;18(sup1):13-21. PMID: 30063864. doi:10.1080/14712598.2018.1474197. PubMed 12 Matteucci C, Grelli S, Balestrieri E, Minutolo A, Argaw-Denboba A, Macchi B, et al. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future Microbiol. 2017;12:141-155. PMID: 28106477. doi:10.2217/fmb-2016-0125. PubMed 13 King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016;102:151-78. PMID: 27450734. doi:10.1016/bs.vh.2016.04.003. PubMed 14 Wang P, Zhang X, Xiang C, Li G, Zhang Y. Thymalfasin combined with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A retrospective study on efficacy, safety, and immunological function. Pak J Med Sci. 2026;42(3):684-691. PMID: 41994384. doi:10.12669/pjms.42.3.13385. PubMed 15 Xu H, Li F, Li B, Yang D, Liu T, Xia Y, et al. Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial. BMC Med. 2026;24(1). PMID: 41749205. doi:10.1186/s12916-026-04740-z. PubMed

References are illustrative of the research literature surrounding this compound. All claims relate to in-vitro and animal models only.

[05]

FAQ

Thymosin Alpha-1 is a synthetic 28-amino-acid acetylated peptide identical to a naturally occurring thymic hormone, first isolated from a thymus fraction that restored immune competence. It is studied chiefly in immune-modulation research. Condor Research supplies it as a 10 mg vial, third-party tested to ≥99% purity by HPLC, strictly for in-vitro research use.

Despite the shared "thymosin" name, they are unrelated peptides with different research areas. Thymosin Alpha-1 is a 28-residue acetylated thymic peptide studied in immune modulation. TB-500 is the active fragment of thymosin β4, a 43-residue actin-binding peptide studied in tissue repair and regeneration. Different sequences, different focus. Both are Research Use Only materials.

The names are misleading: thymosin α1 and thymosin β4 belong to separate peptide families. Thymosin Alpha-1 (28 residues, acetylated) is an immune-focused research peptide; TB-500, derived from thymosin β4 (43 residues), is studied for actin binding and tissue repair. They are not variants of one molecule. Both are supplied strictly for in-vitro use.

Both feature in immunity research but act differently. Thymosin Alpha-1 is a 28-residue thymic peptide studied as an immune modulator. LL-37 is the human cathelicidin-derived antimicrobial peptide, studied for direct antimicrobial activity in innate immunity. So one is broadly immunomodulatory and the other antimicrobial. Both are offered as Research Use Only reference compounds.

Both appear in immune-related research but are structurally and mechanistically distinct. Thymosin Alpha-1 is a 28-residue acetylated thymic peptide studied as an immune modulator. KPV is a three-residue α-MSH C-terminal fragment (Lys-Pro-Val) studied for anti-inflammatory activity. Different size, origin and focus. Both are supplied strictly as in-vitro research materials.

Yes — the N-terminal acetyl group is integral to the molecule's identity and is reflected in the listed acetylated sequence and molecular weight (3108.3). Each lot is tested by an independent third-party laboratory, with identity and purity confirmed by HPLC and mass spec, certifying ≥99% purity. For the batch-specific COA, contact info@condorresearch.com.

Each lot ships with a batch-specific Certificate of Analysis from an independent third-party laboratory, with purity by HPLC certified to ≥99% and identity confirmed by mass spec, which captures synthesis-related impurities such as deletion sequences for a peptide of this length. For the full impurity breakdown on the current Thymosin Alpha-1 lot, request the COA at info@condorresearch.com.

Thymosin Alpha-1 is a water-soluble lyophilized powder, dissolved in a compatible aqueous diluent for in-vitro preparation, with volume chosen to reach the target analytical concentration from the 10 mg vial. Store the sealed vial at -20°C, protected from light (24-month shelf life). This is analytical preparation only; no human or veterinary dosing guidance is provided.

No — Thymosin Alpha-1 is supplied strictly as a Research Use Only (in vitro) reference material: not a medicine, supplement or medical device, and not for human or veterinary administration or consumption. Sales are restricted to professionals and institutions aged 18+. Buyers are responsible for confirming the legality of import in their own jurisdiction.

[06]

Reviews

Leave a review
Earn 250 points for a verified review (account required).
4.7
56 verified reviews
5
79%
4
16%
3
4%
2
2%
1
0%
Apr 2026
High purity, clear labelling

Lyophilised cake was uniform and dissolved fully. Would appreciate a digital COA portal, but the PDF on request worked fine.

Dr. A. Bianchi · University · IT Verified purchase
Mar 2026
Trustworthy supplier

Identity by MS confirmed in our facility. Communication around storage and handling was precise and professional.

K. Wójcik · Research group · PL Verified purchase
Mar 2026
Reference-grade consistency

Reconstitution was clean with no visible particulates. The lot-specific COA matched the assay we ran in-house — purity is exactly as stated.

Dr. M. Hartmann · Research lab · DE Verified purchase
Feb 2026
COA matched our own HPLC

We verify every incoming compound by HPLC; this batch came back within tolerance of the certificate. Dispatch from the EU warehouse was quick.

L. Fischer · University group · AT Verified purchase

Related compounds